ผศ.พญ.ธัญนันท์ เรืองเวทย์วัฒนา ... career...

ผศ.พญ.ธัญนันท์ เรืองเวทย์วัฒนา และ ผศ.พญ. กฤตยิา กอไพศาล

? ?? ??? ????

ORAL PRESENTATION AT WCLC 2011 30 YEARS LYMPHOEPITHELIOMA LUNG CANCER AT MAYO CLINIC

ASCO 2012

WCLC 2013

• "For Houston life" 😘 😘

“I never tried to understand what work-life balance is .... until I came here”

Staying in the quiet places and being with myself, I heard my voices/my thoughts. I held my life in my hand and it was my own. I also restored my heart and made it

fresh again. 😘😘Future is clearer😘😘

I had a chance to change my focus from working to serving my soul. The best part was not about how many projects I have done but it was about the meaning of life

and the future that I have started thinking about it.

Thanks everyone for coming into this chapter of my life.

I will remember all the memories we have shared in the deepest part of my heart.

I will also smile when I look back over this time.

“It has been such a wonderful experience with such a great group of people here”

# Time to go back to my real life 😘 😘

Development of lung cancer treatment in Ramathibodi

Hospital

Translational Science

Bench Work

Network : International & Domestic multicenters

Infrastructure : CRC

Drug Development

in Thailand

Clinic : Multidisciplin

ary team (RLC)

Development of lung cancer treatment in Ramathibodi

Hospital

Translational Science

Bench Work

Network : International & Domestic multicenters

Infrastructure: CRC

Drug Development

in Thailand

Clinic : Multidisciplin

ary team

Multidisciplinary team

1st MDT: 7th October, 2014

Ramathibodi Lung Cancer Consortium (RLC)

ตัวช้ีวดั

เป้าหมาย

ผลด าเนินการ ก่อนจัดตั้ง

RLC

(control) N=81

หลงัจัดตั้ง RLC

N = 200

P-value

Time from first visit to first intervention (median, days)

ลดเวลา

11

2

<0.001 HR=2.01

95%CI; 1.53-2.62

Time from first visit to first treatment (median, days)

ลดเวลา

57

14

<0.001 HR=2.93

95%CI; 2.21-3.89

Number visits from first visit to first treatment (mean +- SD, days)

ลดจ านวน visits

7.98 ± 4.47

2.27 ± 2.70

<0.001

ผลการด าเนินงานและตัวชีว้ัดทมี RLC

ตัวช้ีวดั ALL CONTROL RLC P

Time from 1st visit to 1st imaging study

All N=53

Control N=14

RLC

N=39

Median (days) 7 12.5 6 0.649

Time from 1st visit to 1st biopsy

All N=38

Control N=27

RLC

N=11

Median (days) 14.5 20 2 0.004

Time from 1st visit to surgery All N=71

Control N=26

RLC

N=45

Median (days) 50 77 31 <0.001

Time from 1st visit to 1st Chemotherapy

All N=93

Control N=32

RLC

N=61

Median (days) 20 45 11 <0.001

Time from 1st visit to 1st radiation

All N=33

Control N=10

RLC

N=23

Median (days) 16 19 13 0.247

0.0

00.2

50.5

00.7

51.0

0

0 2 4 6

time (years)

Control RLC

Kaplan-Meier survival estimates

Overall survival rate & time

P-value <0.001 variable

5-year OS rate (%) and mOS (years) P-value

5-year OS rate <0.001

control 33.1

(22.5-44.0)

RLC 45.9

(23.1-66.1)

median survival (years)

<0.001

control

1.5

RLC 4.7

0.0

00.2

50.5

00.7

51.0

0

0 2 4 6

time (years)

Control RLC

Kaplan-Meier survival estimatesStage I-II

0.0

00

.25

0.5

00

.75

1.0

0

0 1 2 3 4 5

time (years)

Control RLC

Kaplan-Meier survival estimatesStage III-IV

HR = 0.32 (0.2-0.5), P<0.001 mOS RLC = 2.9 years mOS control = 0.6 years

• รางวัลชนะเลิศงานพัฒนาคุณภาพ คณะแพทยศ่าสตร์โรงพยาบาลรามาธิบดี เดือน สงิหาคม 2017 • รางวัลชนะเลศิ Team Good Practice ของมหาวทิยาลัยมหดิล เดือน พฤศจกิายน 2017

Prevention

Smoking

Biomarker causing lung cancer

Drugs prevent lung cancer

Bench works

Biomarker

Pathway for lung cancer prevention and

treatment

How to overcome resistance and decrease

AE of targeted drug ?

New effective chemotherapy

Treatment

Clinical trial design

Proper endpoints and biomarkers

Molecular testing

Cooperative network in each region

Targeted Therapy

“Bench to Bedside

Clinical Study”

Drug Discovery and

Development

Changing the Cancer

Treatment Paradigm

PROPOSED CONCEPTS FOR LUNG CANCER RESEARCH

AND CANCER DRUG DEVELOPMENT

Cooperation

Ramathibodi & University-based hospitals

Ramathibodi Lung Cancer Consortium (RLC)

Center for Medical Genomics

Ramathibodi Cancer Center and Biobank

• Molecular alteration in Thai population • Development of diagnostic techniques both in tissue and liquid biopsy • Drug Development

Journal of Thoracic Oncology Vol. 11 No. 5: 613-638

Development of lung cancer treatment in Ramathibodi

Hospital

Translational Science

Bench Work

Network : International &

Domestic multicenters

Infrastructure

Drug Development in

Thailand

Clinic : Multidisciplinary

team

• Lung Cancer Group (RA, CU, SI, Rajavithee)

• Research cooperation (RA, CU, SI, Rajavithee, PM, Songkla, CM)

Thailand Network

• USA

• Japan, Hongkong, Singapore, Taiwan, Korea

International Network

Management in locally advanced and advanced NSCLC : MDT discussion with Dr. Alex Adjei 10 April 2015

2010 RAMATHIBODI-MAYO JOINT CONFERENCE: Update in cancer treatment

12-13 March, 2010 Pullman Hotel, Bangkok

100 Pharmacogenes -next generation sequencing in chemotherapy treated patients.

Development of lung cancer treatment in Ramathibodi

Hospital

Translational Science

Bench Work

Network : International &

Domestic multicenters

Infrastructure

Drug Development in

Thailand

Clinic : Multidisciplinary

team

https://www.conquer.org/grants-awards/funding-opportunities

http://www.esmo.org/Career-Development/Oncology-

Fellowships/Fellowship-Offers

Grants Durations Award

1. Translational Research Unit Visits

3-4 days 1,000 Euro

2. ESMO European Integration Fellowship

6 weeks 5,000 Euro

3. ESMO Palliative Care Fellowships

1-3 months

5,000 Euro

4. ESMO Translational Research 1 year 40,000 Euro

5. ESMO Clinical Research Fellowships

1 year 40,000 Euro

6. Clinical Unit Visits 6 weeks 5,000 Euro

7. Travel grants for ESMO young oncologists

ESMO meeting

Travel grants

http://www.esmo.org/Career-Development/Oncology-Fellowships/Fellowship-

Offers

https://www.iaslc.org/fellowship/announcements

The best results will be realised when we all work together (Multicenter)

Oncologists Pathologists

Pulmonologists

Surgeons

Radiation oncologists Nurses

Patients + Thailand

Molecular pathologists

Radiologists

Cytologists

Pharmacist

Nuclear medicine